MUC1 (HLA-B*07:02) VPGWGIALL

The MUC1 950–958 peptide (sequence: STAPPVHNV) is a defined HLA-A*02:01-restricted epitope derived from human Mucin-1 (MUC1; UniProt P15941). It is synthesized in its naturally presented MHC class I format and is optimized for the stimulation and analysis of antigen-specific CD8⁺ T cells. This single epitope peptide (IEDB ID 459700) enables precise functional interrogation of MUC1-specific cytotoxic T-cell responses in immunological and oncological research. Scientific Background MUC1 is a transmembrane mucin expressed on epithelial cells and widely recognized as a tumor-associated antigen. In malignant transformation, MUC1 becomes: Highly overexpressed Aberrantly glycosylated Mislocalized within the cell These alterations contribute to tumor progression, immune modulation, and altered signaling pathways. Because of these tumor-specific changes, MUC1-derived epitopes are frequently recognized by the immune system and have been validated in numerous CD8⁺ T-cell studies. The HLA-A*02:01-restricted epitope STAPPVHNV represents a well-characterized target for antigen-specific T-cell activation and immune monitoring. Applications The MUC1 950–958 peptide is suitable for: IFN-γ ELISpot assays Intracellular cytokine staining (ICS) Cytotoxicity assays T-cell proliferation assays Antigen-specific T-cell expansion Dendritic cell pulsing Immune monitoring in cancer research Its defined sequence allows focused analysis of epitope-specific CD8⁺ T-cell responses, making it particularly useful for mechanistic studies and translational oncology research. Positioning Within the MUC1 Research Portfolio While overlapping peptide pools enable full-length antigen screening and epitope discovery, single defined peptides such as MUC1 950–958 allow high-specificity functional validation and quantitative immune monitoring in HLA-typed cohorts. This peptide is therefore ideally suited for: Targeted immune response analysis Validation of vaccine-induced T-cell responses Monitoring of MUC1-directed immunotherapies

The HUMAN MUC1 Peptide Pool by peptides&elephants is a highly reliable, quality-controlled, overlapping peptide pool covering the complete human Mucin‑1 protein (UniProt ID P15941). The peptide pool is optimized for robust detection and characterization of T-cell responses in immunological research and cancer biomarker discovery. One unit allows the stimulation of 2,5 x 108 cells. The initial set of 311 overlapping 15-mer peptides (with an 11-residue overlap) was reduced to 115 unique peptides by eliminating 196 redundant sequences. Full protein coverage – ensures that all potential epitopes in MUC1 are included Why MUC1 Matters in T‑cell Studies Tumor-associated antigen: MUC1 is a well-known tumor-associated transmembrane mucin heavily overexpressed in many cancers—including breast, bladder, pancreatic and ovarian cancers.  While the regularly glycosylated MUC1 forms a protective barrier on the surface of epithelial cells in healthy tissues, MUC1 is  aberrantly highly expressed,  aberrantly glycosylated and  has altered localization  in cancer cells. It plays significant roles in cell signaling, tumor progression, and immune evasion. T-cell immunogenicity: Numerous MUC1-derived peptides have been validated as CD8⁺ T-cell epitopes in both preclinical models and human studies.  Vaccine and immune monitoring relevance: MUC1 peptide vaccines have been used to induce cytotoxic T‑cell responses in preclinical and clinical settings. Notably, MUC1—also known as Cancer Antigen 15-3 (CA 15-3)—serves as a widely used tumor marker for monitoring disease progression in breast cancer patients. Intended Use of HUMAN MUC1 Peptide Pool  Designed for T‑cell assays, including ELISpot, intracellular cytokine staining (ICS), cytotoxicity assays, proliferation assays, dendritic‑cell pulsing, immune monitoring, T‑cell expansion, and epitope discovery. Also well-suited for cancer biomarker research, especially breast and epithelial cancers.